BioSpace News Archive

Drug Development

Exicure to Present at the AACR Annual Meeting 2019

Data presented in collaboration with Celldex show that Exicure’s technology leads to a more potent anti-tumor response when combined with Celldex’s CDX-301

April 1, 2019
·
4 min read
Policy

Vizient Submits Recommendation to CMS for Changes to Hospital Star Ratings Methodology

In response to the Centers for Medicare and Medicaid Services request for public input on the methodology of the Overall Hospital Quality Star Rating on the Hospital Compare website, Vizient has submitted a detailed proposal for a more clinically grounded approach for the ratings.

April 1, 2019
·
2 min read
Drug Development

BerGenBio: Bemcentinib in Combination With low-dose Chemotherapy Achieves Efficacy Endpoint in AML Patients

Phase II trial evaluating bemcentinib in combination with low-dose chemotherapy in AML patients unfit for intensive therapy

April 1, 2019
·
7 min read
Business

Aerie Pharmaceuticals Announces Appointment of Gianluca Corbinelli as Chief Commercial Officer - Europe

Aerie Pharmaceuticals, Inc. announced the appointment of Gianluca Corbinelli as Chief Commercial Officer - Europe, reporting to Thomas Mitro, Aerie’s President and Chief Operating Officer.

April 1, 2019
·
6 min read
FDA

Selumetinib Granted U.S. Breakthrough Therapy Designation in Neurofibromatosis Type 1

Designation Based on Phase 2 SPRINT Trial in Pediatric Patients with NF1 Plexiform Neurofibromas

April 1, 2019
·
7 min read
Deals

SpringWorks Therapeutics Completes $125 Million Series B Financing

Three Clinical Trials Expected to Commence in the First Half of 2019, Including Two Late-Stage Rare Oncology Programs and First Targeted Oncology Program in Collaboration with BeiGene

April 1, 2019
·
3 min read
FDA

Selumetinib Granted US Breakthrough Therapy Designation in Neurofibromatosis Type 1

Designation based on Phase II SPRINT trial in pediatric patients with NF1 plexiform neurofibromas

April 1, 2019
·
5 min read
Pharm Country

Growth in Telehealth from 2016 to 2017 Outpaces Other Venues of Care Studied in Second Annual FAIR Health Report

FAIR Health Market Indices and Trending Reports Once Again Bring Valuable Visibility into Patient Migratory Patterns and Healthcare Costs

April 1, 2019
·
6 min read
Policy

Merck’s KEYTRUDA® (pembrolizumab) Approved in China for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) in Combination with Chemotherapy

KEYTRUDA is First Anti-PD-1 Therapy to be Approved in Multiple Tumor Types in China

April 1, 2019
·
29 min read
Biotech Bay

NovaBay Pharmaceuticals Announces Investments of $5 Million to Support U.S. Avenova Commercialization Strategy

NovaBay® Pharmaceuticals, Inc. announces investments totaling $5 million to support the recent strategic shift in its U.S. commercialization strategy aimed at driving growth in Avenova sales while maintaining cost effectiveness.

April 1, 2019
·
4 min read